IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation.
Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N.
Kato T, et al. Among authors: tanaka n.
BMC Cancer. 2022 Dec 9;22(1):1292. doi: 10.1186/s12885-022-10398-6.
BMC Cancer. 2022.
PMID: 36494792
Free PMC article.
Clinical Trial.